SOLV
Solventum
$73.56
▼ 2.5%Updated Today 7:15 PM ET
▲ Up 3.9% over the last 12 months
Market Cap
$13.06B
P/E
9.16x
Forward P/E (est.)
6.54x
ROE
30.7%
Revenue Growth
-0.6%
EPS Growth
276.2%
Profit Margin
17.3%
FCF Yield
—
Debt / Equity
1x
ROIC
17.0%
Interest Coverage
—
Current Ratio
1.07x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
62/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what SOLV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. SOLV trades near $73.56, around its 50-day average ($73.12) and 200-day average ($74.36). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 47 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. SOLV's is $2.70 (~3.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month SOLV found buyers near $72.74 (support) and sellers near $83.42 (resistance); its 52-week range is $62.38–$88.20. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.6× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Solventum (SOLV) is a large-cap company in the Health Care Technology industry, part of the Health Care sector of the S&P 500, with a market value around $13.06B.
In its latest reported year it generated about $8.32B in revenue and $1.56B in net profit.
Our model rates SOLV Favorable (62/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
3Y CAGR
0.8%
Revenue moved from $8.13B in 2022 to $8.32B in 2025, a 0.8% compound annual growth rate. The most recent year declined 0.6% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
53.5%
Operating Margin
26.2%
Net Margin
18.7%
ROE
30.7%
Solventum keeps about 17.3% of each sales dollar as net profit, with a 53.5% gross margin and 26.2% operating margin. Return on equity is 30.7% and return on invested capital about 17.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$5.04B
Net Debt
$4.47B
Net Debt / EBITDA
2.05x
Debt / Equity
1x
Leverage: debt-to-equity is 1.0x, with a current ratio of 1.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $5.04B of total debt against $561.00M of cash.
Operating CF
$369.00M
Free Cash Flow
-$10.00M
FCF Margin
-0.1%
In the latest year Solventum produced about $369.00M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
9.16x
P/S
1.6x
P/B
2.68x
EV / EBITDA
6.64x
SOLV trades at 9.2x trailing earnings (about 6.5x on estimated forward earnings), 1.6x sales, and 2.7x book value. That is an undemanding multiple — potentially cheap if the business is stable.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How SOLV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), SOLV ranks #16 of 59 by our overall rating. It trades at a discount versus the sector on earnings (9.2x P/E vs. 25.4x median) with a higher return on equity (30.7% vs. 14.9%) and slower revenue growth (-0.6% vs. 7.9%).
P/E vs sector
9.2x
median 25.4x
ROE vs sector
30.7%
median 14.9%
Growth vs sector
-0.6%
median 7.9%
Sector rank
#16
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$52.94 – $95.30
vs. $73.56 today · expected CAGR -6% – 5%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $8.57B | $8.83B | $9.10B | $9.37B | $9.65B |
| Net income | $1.63B | $1.68B | $1.73B | $1.78B | $1.83B |
| EPS | $9.41 | $9.69 | $9.98 | $10.28 | $10.59 |
| Share price (low) | $47.04 | $48.45 | $49.90 | $51.40 | $52.94 |
| Share price (high) | $84.67 | $87.21 | $89.83 | $92.52 | $95.30 |
| CAGR (low–high) | -36% / 15% | -19% / 9% | -12% / 7% | -9% / 6% | -6% / 5% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for SOLV:
- High net margins (17.3%) point to pricing power or efficiency.
- Strong return on equity (30.7%) shows capital is put to work well.
- Our model's overall read is Favorable (62/100).
The case against SOLV:
- Revenue growth is slow/negative (-0.6%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Growth risk — sluggish revenue (-0.6%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Solventum is a large-cap health care business with shrinking revenue, with solid profitability, and a heavier debt load to watch. It trades at 9.2x earnings, which our model scores Favorable (62/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.